For individuals facing Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the emergence of Tafamidis and Tafamidis meglumine represents a genuine advancement . These innovative therapies stabilize the transthyretin protein, slowing its harmful build-up and alleviating the i